Retail Investors Furious over Pharmaceutical and Biotech Stocks… Share Prices Fall After Paid-in Capital Increase

조선일보

Lean Right

Factuality

Ownership

Pharmaceutical and biotech companies are facing backlash from minority shareholders, including sharp stock price drops, as they conduct paid-in capital increases to raise funds during a high-interest rate environment. While the objectives vary by company—ranging from M&A, facility investment, to debt repayment—concerns regarding equity dilution have intensified. Experts advise investors to carefully analyze the purpose of the capital increase be…